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Background: Acute infection is a well-established risk factor of cardiovascular inflammation 
increasing the risk for a cardiovascular complication within the first weeks after infection. 
However, the nature of the processes underlying such aggravation remains unclear. 
Lipopolysaccharide (LPS) derived from Gram-negative bacteria is a potent activator of 
circulating immune cells including neutrophils, which foster inflammation through discharge 
of neutrophil extracellular traps (NETs). Here we utilize a model of endotoxinemia to link 
acute infection and subsequent neutrophil activation with acceleration of vascular 
inflammation   
Methods: Acute infection was mimicked by injection of a single dose of LPS into 
hypercholesterolemic mice. Atherosclerosis burden was studied by histomorphometric 
analysis of the aortic root. Arterial myeloid cell adhesion was quantified by intravital 
microscopy. 
Results: LPS treatment rapidly enhanced atherosclerotic lesion size by expansion of the 
lesional myeloid cell accumulation. LPS treatment led to the deposition of NETs along the 
arterial lumen and inhibition of NET release annulled lesion expansion during endotoxinemia, 
thus suggesting that NETs regulate myeloid cell recruitment. To study the mechanism of 
monocyte adhesion to NETs, we employed in vitro adhesion assays and biophysical 
approaches. In these experiments, NET-resident histone H2a attracted monocytes in a 
receptor-independent, surface charge-dependent fashion. Therapeutic neutralization of histone 
H2a by antibodies or by in silico designed cyclical peptides enables us to reduce luminal 
monocyte adhesion and lesion expansion during endotoxinemia.   
Conclusions: Our study shows, that NET-associated histone H2a mediates charge-dependent 
monocyte adhesion to NETs and accelerates atherosclerosis during endotoxinemia.  
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Non-standard Abbreviations and Acronyms  
AFM  Atomic force microscopy 
CHIP  Cyclical Histone 2a Interference Peptide  
DAPI  4',6-Diamidino-2-phenylindol  
LPS lipopolysaccharide 
MPO myeloperoxidase 
NET neutrophil extracellular trap 
PAD  protein arginine deiminases  
PFA  paraformaldehyde 













What is new?  
• Neutrophils and specifically neutrophil extracellular traps (NET) control accelerated 
atherosclerosis during endotoxinemia. 
• NET-resident histone H2a heightens arterial monocyte recruitment in endotoxinemia 
in a mechanism involving electrostatic charge interaction. 
 
What are the clinical implications?  
• NET-driven arterial monocyte recruitment is a mechanism operational during 
endotoxinemia. 
• Therapeutic neutralization of NET-resident cationic molecules including histone H2a 
by use of antibodies or peptides may protect cardiovascular risk patients during an 












Atherosclerosis is a lipid-driven chronic inflammation of the arterial vessel wall. In its late 
stages, atherosclerosis is the underlying pathophysiology of myocardial infarction and stroke 
and hence the leading cause of mortality worldwide. Monocytes and macrophages hold 
crucial roles throughout all stages of atherosclerosis as they contribute to lipid modification 
and respond with a pronounced inflammatory response upon uptake of modified lipids1. With 
only limited numbers of macrophages residing in large arteries, the vast majority of 
monocytic cells needs to be de novo recruited in a process known as the leukocyte recruitment 
cascade, which is orchestrated by fine-tuned interactions of selectins, chemokines, and 
integrins and their respective receptors2. In recent years, studies have provided evidence for 
the contribution of neutrophils to the arterial monocyte recruitment. Herein, neutrophils 
deposit preformed chemoattractants on endothelial cells or activate endothelial cells directly 
to stimulate monocyte adhesion3-7.  
Multiple bacterial and viral pathogens have been associated with atherosclerosis by 
seroepidemiologial studies and identification of the infectious agent in human atherosclerotic 
tissue. Moreover, there is strong clinical evidence for the acceleration of arterial inflammation 
by acute infection8. As an example, urinary tract infection and bacteremia associate with an 
increase in the short-term risk of myocardial infarction9,10. Most striking data, however are 
available from patients with pneumonia, with the risk of myocardial infarction peaking at the 
onset of infection and is proportional to the severity of illness11,12. Division of Gram-negative 
bacteria or their elimination leads to release of lipopolysaccharide (LPS) into the blood 
stream, i. e. endotoxinemia. Neutrophils are rapidly activated by LPS possibly leading to the 
release of neutrophil extracellular traps (NETs), a complex structure composed of nuclear 
chromatin and proteins of nuclear cytoplasmatic and granule origin13. Since proteins reported 










luminal side of large arteries14, we here hypothesized that LPS-triggered NET release acts as a 
link between endotoxinemia and heightened vascular inflammation by triggering monocyte 
recruitment.    
 
Methods 
An expanded method section can be found in online supplement 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 
Animal experiments 
We surveyed atheroprogression in Apoe-/- or Apoe-/-Cx3cr1GFP reporter mice on C57Bl/6J 
background after 4 weeks of high-fat diet (HFD) (21% fat, Ssniff). Endotoxinemia was 
induced by intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, Escherichia coli, 
O111:B4, Sigma Aldrich, 1 mg/kg BW, i.p.). Control mice received vehicle (PBS, 100 µl, 
i.p.). Thereafter, atherosclerotic lesions were analyzed in aortic root sections or cell adhesion 
was studied by intravital microscopy of the left carotid artery. To assess the effect of NETs 
we blocked NET-formation with BB Cl-amidine (1 mg/kg BW, Cayman Chemical 
Company). In additional experiments, mice received antibodies to histone H2a (20 µg/mouse, 
Biorbyt), its respective IgG isotype control (Jackson ImmunoResearch), or a cyclical histone 
2A interference peptide (CHIP, 5 mg/kg BW). All animal experiments were approved by the 
local ethics committee and performed in accordance with institutional guidelines. 
Intravital microscopy 
Leukocyte-endothelial interactions along the carotid artery were analyzed in Apoe-/-Cx3cr1GFP 
reporter mice by intravital microscopy as previously reported3-5. In brief, mice were placed in 
supine position, and the right jugular vein was cannulated with a catheter for antibody 










Ly6G (1 μg; clone 1A8; BioLegend) and 4',6-Diamidino-2-phenylindol (DAPI, Thermo 
Fischer). Using an Olympus BX51 microscope equipped with a Hamamatsu 9100-02 
EMCCD camera, and a 10× saline-immersion objective movies of 30 s were acquired and 
analyzed offline. In the carotid artery, one field of view was analyzed per mouse. gfp 
expressing cells were considered monocytes. For identification of NET like structures, the 
original DAPI image was transformed into a 8 bit gray scale image and subsequently 
thresholded. Particles in the latter image were quantified and particles above 80 px2 and a 
circularity below 0.75 were considered NET like structures.  
Human samples 
All in vitro experiments were performed with peripheral human white blood cells donated 
from healthy volunteers. Blood sampling was approved by the Klinikum der Univerität 
München ethics board and participants gave written informed consent. 
Plasma samples from previously described IRB-approved biorepositories at Brigham and 
Women’s Hospital15 were analyzed from patients with Gram-negative rod bacteremia or 
sepsis with cardiovascular risk factors and compared with those from age-matched controls 
with cardiovascular risk factors.   
Statistics 
All statistics analysis was performed by using GraphPad Prism 8 software. Outliers have been 
determined by Grubbs' test with α=0.05. To test normal distribution, the Shapiro-Wilk test 
was used. If normality was passed, data were tested by two-tailed unpaired t-test or one-way 
ANOVA test. The Mann-Whitney test or Kurskal-Wallis test with Dunn’s correction was 
performed when data were not normally distributed. In all used tests a 95% confidence 
interval was utilized with p<0.05 was assumed as significant difference. All data are 












NETs induce luminal myeloid cell adhesion in atherosclerosis during endotoxinemia 
To investigate the effect of endotoxinemia on myeloid cell recruitment during 
atheroprogression, Apoe-/- mice were fed a high fed diet for 4 weeks and injected with LPS for 
4 hours (Figure 1A). Treatment in this way resulted in the striking expansion of 
atherosclerotic lesion sizes (Figure 1B). While plasma cholesterol and triglyceride levels 
were not affected by treatment in this way, counts of circulating neutrophils and monocytes 
were depleted (Figure IA-F in the Data Supplement) likely due to margination and 
extravasation of activated myeloid cells. Indeed, the number of neutrophils, monocytes and 
macrophages recruited to atherosclerotic lesions as well as to inflamed aorta was drastically 
increased in LPS-treated mice (Figure 1C/D, Figure IG/H in the Data Supplement). This 
notion was confirmed by use of intravital microscopy of carotid arteries performed in Apoe-/-
Cx3cr1eGFP mice. There, LPS enhanced adhesion of both GFP+ monocytes as well as of 
antibody-labeled neutrophils (Figure 1E/F).  
 LPS is known to trigger the release of NETs16 and hence we hypothesized that in our 
experimental setting NETs may contribute to heightened neutrophil and monocyte 
recruitment. Intravital microscopy permitted to visualize DAPI+ structures with a NET-like 
shape in the lumen of mice receiving LPS (Figure 1G/H). Additionally, cell-free DNA as 
well as DNA-MPO complexes, a plasma marker of NETs, are strikingly increased in the 
plasma of mice with endotoxinemia (Figure II/J in the Data Supplement). Of note, plasma 
dsDNA correlated with the number of aortic myeloid cells as well as with plasma DNA-MPO 
complexes suggesting that plasma dsDNA is a valid surrogate marker of NETs predicting 
aortic cell infiltration (Figure IK-M in the Data Supplement). Finally, plasma DNA-MPO 
complexes correlated with plasma endotoxin levels indicating that LPS directly induces NET 










assessed the amount of plasma circulating cell free dsDNA, a surrogate marker of NETs, in 
cardiovascular risk patients (Table I in the Data supplement) admitted to the hospital with 
Gram-negative rod bacteremia or sepsis. Here hospitalized patients with confirmed Gram-
negative rod bacteremia or sepsis presented with significantly higher DNA levels compared to 
hospitalized matched controls exhibiting the same cardiovascular risk profile but without 
Gram-negative rod bacteremia or sepsis (Figure IM in the Data Supplement). Of note, 
patients with Gram-negative rod bacteremia or sepsis had higher blood neutrophil counts as 
compared to the respective control group and circulating neutrophil counts across both groups 
of patients correlated with plasma dsDNA levels.  
To test if NETs along the arterial lumen would contribute to the atherosclerosis 
phenotype observed in endotoxinemic mice, we treated mice with BB Cl-amidine, a potent 
inhibitor of protein arginine deiminases (PADs) with favorable pharmacokinetics in terms of 
plasma half-life and EC50. BB Cl-amidine delivery in endotoxinemic mice drastically reduced 
cell-free DNA in the plasma (Figure II in the Data Supplement), while MPO-DNA 
complexes were not detectable in this group. Intravital imaging confirmed that BB Cl-amidine 
treatment abrogated luminal NET release in response to stimulation with LPS for 4 hours 
(Figure 1G/H). In addition, heightened lesion formation as well as lesional accumulation of 
myeloid cells in response to LPS was completely abolished (Figure 1B-D, Figure IG/H in 
the Data Supplement). In agreement herewith, BB Cl-amidine treatment led to a vast 
reduction of arterial myeloid cell adhesion (Figure 1E/F) suggesting that luminal NETs 
promote arterial myeloid cell adhesion during endotoxinemia.    
NETs promote monocyte adhesion independent of receptor signaling 
To study how NETs would promote monocyte adhesion, we allowed human classical 
monocytes, a proatherogenic monocyte subsets17,18, to sediment on NETs in vitro. Indeed, we 










Fluorescence imaging revealed that these classical monocytes predominantly adhered directly 
to the NET scaffold and inhibition of monocyte adhesion after NET degradation with DNase I 
confirmed the importance of NETs in static monocyte adhesion (Figure 2A/B). Of note, such 
finding could also be recapitulated when using CD4+ T cells instead of monocytes (Figure 
IIA in the Data Supplement). To transfer these findings to a physiologically relevant setting, 
we initiated NET release in adherent human neutrophils and perfused classical monocytes in a 
flow chamber assay. As for the static adhesion assay, we found that monocytes primarily 
bound to DNA fibers and that degradation of NETs abolished adhesion evoked by activated 
neutrophils (Figure 2C/D). Similar data sets were obtained when NETs were induced on 
TNF-activated endothelial cells. Here, a higher number of classical monocytes was found to 
adhere at baseline, likely as a consequence of direct monocyte-endothelial cell interaction. 
The number of adherent monocytes under static or flow conditions, however, significantly 
increased when NETs were induced on endothelial cells, an effect fully reversed upon DNase 
I degradation (Figure IIB/C in the Data Supplement).  
 These observations are reminiscent of earlier work showing that proteins typically 
found in NETs or NETs themselves can increase cell adhesion by engaging chemokine 
receptor signaling and leukocyte integrin activation2,19-22. Thus, we neutralized chemokine 
receptors (Figure 2E), receptors of alarmins (Figure 2F, Figure IID in the Data 
Supplement), or integrins (Figure 2G) prior to incubation with NETs. Much to our surprise, 
none of these treatments impacted on adhesion evoked by NETs. Thus we suspected that the 
adhesion evoked by NETs may be signaling independent. Indeed, depletion of calcium by use 
of a chelator did not affect NET-mediated adhesion (Figure IIE in the Data Supplement). In 
addition, abrogation of signaling of G-protein coupled receptors by pertussis toxin or even 










monocytes to NETs (Figure 2H/I). Taken together, these data indicate that monocyte 
adhesion to NETs is independent of receptor signaling.  
NET-resident histone H2a attracts monocytes electrostatically 
Given the signaling-independent adhesion of monocytes to NETs, we assumed that 
biophysical interactions such as electrostatic charges could be important in this process. In 
fact, monocytes present an overall negative surface charge (ζ potential -10.51±0.69 mV), 
while NETs are decorated with highly cationic proteins. To test the importance of charge 
interaction in adhesion of classical monocytes to NETs, monocytes were incubated with either 
cholesterol sulfate or oleylamine. Cholesterol sulfate is a negatively-charged steroid lipid, 
whereas oleylamine is a positively-charged unsaturated fatty acid. Both lipids integrate with 
their lipophilic part into the phospholipid bilayer of the cell membrane and hence allow 
manipulating cell surface charge. In our hands, incubation with cholesterol sulfate or 
oleyelamine rendered monocyte surface charges more negative or more positive, respectively 
(Figure 3A/B). To assess the relevance of the monocyte surface charge during adhesion to 
NETs we allowed human classical monocytes of different surface charges to adhere to NETs. 
In these experiments we were able to generate a stringent correlation with more negative 
surface charges resulting in higher monocyte adhesion and vice versa (Figure 3C). To assess 
the physical properties of charge-dependent adhesion in more depth, we performed atomic 
force spectroscopy with a monocyte immobilized at the tip of the cantilever. Atomic force 
microscopy (AFM) is a scanning probe microscope with piezoelectric elements to move the 
spring like cantilever. The deflecting cantilever is used to directly measure forces acting on 
the monocyte. A force-distance curve reports on the contact force (I), the force until 
maximum adhesion (II), the forces needed to fully detach the monocyte from the NET (III) 
and the distance of this detachment (IV) (Figure 3D). Classical monocytes with different 










on NETs. Manipulation of the monocyte surface charges impacted on the maximum adhesion 
force, the detachment force and the detachment distance to separate monocytes from NETs, 
the energy required to separate the monocyte from the NET, and the adhesion frequency. 
Overall, NET-adhesion strength and the ability to adhere to NETs was heightened when 
monocytes were rendered more negatively charged and opposite effects were found in less 
negatively charged monocytes (Figure 3E-I, Figure IIIA-H in the Data Supplement), thus 
confirming the concept of charge-driven monocyte adhesion.  
Neutrophil extracellular traps are decorated with a large array of granule-derived, 
cytoplasmatic, and nuclear proteins. Proteomics of NETs allowed the identification of 73 
enriched polypeptides of which two clusters exhibited cationic surface charge as deferred 
from the peptides isoelectric point. One cluster was centered on nuclear histones of which 
histone H2a is the most abundant one. A second cluster revealed antimicrobial polypeptides 
with myeloperoxidase (MPO) and cathepsin G being the two candidates characterized by both 
cationic charge and high abundance (Figure 3J, Table II in the Data Supplement). To 
assess the contribution of these NET-resident proteins towards monocyte adhesion, we treated 
NETs with antibodies towards these polypeptides and recorded adhesion of human classical 
monocytes. In these studies, neutralization of antimicrobial polypeptides abundantly found in 
NETs (MPO, cathepsin G) and of such previously found to contribute to monocyte adhesion 
(LL37, elastase, proteinase 3, HNP1-3) yielded no effect (Figure 3K, Figure IIII in the Data 
Supplement)4,5,23. In addition, neutralization of highly abundant S100A8/9 peptides failed to 
reduce monocyte adhesion (Figure IIIJ in the Data Supplement).  However, neutralization 
of histone H2a, the most abundant nuclear protein found in NETs, fully abrogated NET-
driven monocyte adhesion (Figure 3K). High resolution confocal microscopy revealed that 
monocytes indeed bound to NET-resident histone H2a (Figure 3L). Finally, histone H2a 










confirming our understanding of charge-mediated monocyte adhesion. When studying the 
binding of histone H2a to monocyte subsets we found that a similar percentage of both 
classical and non-classical monocytes reacted with histone H2a (Figure IIIK in the Data 
Supplement). However, histone H2a bound in much higher intensity to classical monocytes 
when compared to their non-classical counterparts irrespective if they expressed Slan or not 
(Figure IIIL in the Data Supplement). 
Therapeutic neutralization of histone H2a diminishes arterial monocyte adhesion and 
atheroprogression during endotoxinemia 
Thus far our data suggest that histone H2a presented in NETs released during endotoxinemia 
causes myeloid cell adhesion, a process dramatically accelerating atheroprogression.  Hence, 
we devised a protocol aimed at halting histone H2a-induced monocyte adhesion in vivo. 
Herein, a histone H2a neutralizing antibody or an isotype control IgG were administered in 
hypercholesterolemic mice treated with LPS for 4 hours and luminal adhesive events were 
studied by intravital microscopy (Figure 4A). While treatment with histone H2a targeting 
antibodies did not impact on the presence of luminal NET-like structures and the number of 
circulating leukocytes, adhesion of myeloid cells was significantly reduced (Figure 4B-D, 
Figure IVA/B in the Data Supplement). Whereas, antibody targeting in vivo may be 
associated to undesired side effects, we aimed at generating an alternative interference 
strategy. A resurgence of peptides as therapeutic agents to treat many diseases, especially for 
cardiovascular disease, has inspired us to develop peptidic inhibitors to neutralize histone 
H2a. Peptides contain several advantages such as ease of synthesis and optimization to 
improve pharmacokinetic and binding properties, large-scale and cost-effective production 
and applicability to conjugate with specific probes for drug delivery or for using as imaging 
tools24.  Moreover, we have previously demonstrated and proven that monocyte adhesion can 










histone H4 can be neutralized by the cyclic peptide26. By use of the same structure-based 
approaches as in our previous work we in silico designed and developed peptides targeting 
histone H2a. A few peptide candidates were selected based on binding free energy and visual 
inspection of the interactions between the candidates and the N-terminal tail of histone H2a 
for further synthesis and functional characterization. The most potent peptide called Cyclical 
Histone 2a Interference Peptide (CHIP) bound with the N-terminal domain of histone 2A.The 
electrostatic interactions between positively charged residues (Arg and Lys) of histone H2a 
with negatively charged residues (Asp and Glu) of CHIP and H-bond interactions promoted a 
stable complex formation (Figure 4E). To test the functionality of this peptide we first 
performed in vitro experiments. Herein, pretreatment of NETs with CHIP reduced adhesion 
significantly (Figure 4F). Biophysically, CHIP reduced the interaction strength of monocytes 
and NETs as shown by atomic force microscopy (Figure 4G-I). Given these encouraging 
findings, we aimed at testing CHIP in vivo. Delivery of CHIP to hypercholesterolemic mice 
receiving LPS for 4 hours did not impact on the presence of NET-like structures in the arterial 
lumen, but significantly diminished arterial adhesion of neutrophils and monocytes (Figure 
4J-M). Beyond impacting on luminal events, CHIP allowed to drastically reduce 
atherosclerotic lesion sizes (Figure 4O). These changes in lesion size were not associated 
with differences in blood counts or plasma lipid levels (Figure IVC-F in the Data 
Supplement). The lesions of mice treated with CHIP were characterized by the accumulation 
of less neutrophils and macrophages (Figure 4P-R). In line herewith, aortic neutrophil and 
monocyte numbers were strikingly reduced by CHIP (Figure IVG/H in the Data 
Supplement). Taken together, neutralization of histone H2a by antibodies or peptides allows 













Atherosclerosis is the leading cause of mortality in Western society. Excess mortality from 
cardiovascular disease during influenza epidemics was first recognized early in the 20th 
century, but the specific association of influenza and other infections with myocardial 
infarction was not characterized until decades later. In fact, over the last 20 years 
epidemiological studies have consistently demonstrated the association between acute 
infection with multiple bacterial and viral pathogens and the short term increase in 
cardiovascular complications8. As an example, a self-controlled case series involving U.S. 
veterans showed a remarkable increase in the risk of myocardial infarction during the first 15 
days after hospitalization for acute bacterial pneumonia, to a risk that was 48 times higher 
than that in any 15-day period during the year before or after the onset of infection27. An 
increase in the short-term risk of myocardial infarction has also been described in association 
with urinary tract infection and bacteremia9,10. The strength and temporal pattern of the 
association between acute infections and an increased risk of myocardial infarction suggest a 
causal relationship. Because the association has been shown with a variety of pathogens, sites 
of infection, and the association is stronger and lasts longer when the infection is more severe, 
it is likely that the infection and the host response to infection are major determinants in this 
relationship. Here we used a model of endotoxinemia to mimic acute, severe infection. In 
these experiments, administration of endotoxin induces a rapid expansion of atherosclerotic 
lesions characterized by extension of the lesional myeloid cell compartment. This increase 
was fully abrogated when release of NETs was pharmacologically inhibited. Our studies 
identify a mechanism that centers on monocyte adhesion to luminal NETs in general and to 
NET-resident histone H2a in particular. Neutralization of histone H2a by antibodies or by in 










lesional myeloid cell accumulation, thus providing a potential strategy for improved care of 
patients at risk of cardiovascular events and experiencing an acute infection. 
 Since our study was performed with endotoxin stimulation only, this may be perceived 
as limitation in the applicability of our study to clinical scenarios. However, an increased risk 
for cardiovascular complications after an acute infections has been observed for numerous 
pathogens, including viruses such as influenza virus or respiratory syncytial virus, Gram-
positive bacteria including Streptococcus pneumonia and Staphylococcus aureus, as well as 
Gram-negative bacteria like Escherichia coli and Haemophilus influenza8,10,12,28. Interestingly, 
NET release is triggered by a variety of stimuli including all of the pathogens listed above29 
and hence the NET-centered mechanism identified in our study may in part be applicable to a 
large variety of pathogen-associated cardiovascular complications although confirmation in 
additional studies is required.   
 Neutrophils have previously been reported to pave the way for inflammatory 
monocytes into developing atherosclerotic lesions. Rendering mice neutropenic during initial 
stages of atherosclerosis diminishes lesion sizes as well as lesion composition, with lowered 
macrophage accumulation30. Neutrophils stimulate various mechanisms that promote 
monocyte recruitment. Among these, secretion of chemotactic proteins stands out as an 
important mechanism for arterial monocyte recruitment. Cathepsin G, cathelicidin, complexes 
formed of neutrophil-derived α-defensin and platelet-borne CCL5, and CCL2 released from 
neutrophils in a circadian fashion were shown to induce firm monocyte adhesion in mouse 
models of vascular inflammation when immobilized on arterial endothelial cells3-5,31. 
However, all these ligands bind to specific receptors and increase adhesion through increased 
integrin affinity and avidity. In our study we identify electrostatic interactions between 
cationic histone H2a and negatively charged classical monocyte surfaces as a novel 










Histone H2a combines abundance within NETs and surface charge and may hence stand out 
as an important epitope for monocyte adhesion. However, other histone isotypes may engage 
similar activities as they are comparable in abundance and charge within NETs. Of note, a 
recent study has shown that activated smooth muscle cells residing in the fibrous cap of 
advanced atherosclerotic lesions stimulate neutrophils to release NETs. These are rich in 
cytotoxic histone H4 that can puncture human and murine SMCs leading to their death and, 
when re-occurring, thinning of the fibrous cap26. Thus, therapeutic neutralization of histone 
epitopes may exert a dual beneficial effect allowing to limit macrophage burden and fibrous 
cap thinning32,33.   
The mechanism of NET-driven monocyte recruitment is receptor independent and 
hence lacks specificity. In fact, in unpublished observations we also found that neutrophils 
adhere to NETs. Consequently, continued inhibition of neutrophil adhesion to NETs may 
lower the number of neutrophils at sites of inflammation and hereby reduce local NET 
burden. In addition, surgical removal of tumors (especially colorectal cancer) is frequently 
associated with bacteremia and NETs triggered in such settings have been suggested to 
promote immobilization of tumor cells in vascular beds thus promoting formation of 
metastases34-36. Mechanistically, some studies reported beta1 integrins on tumor cells to 
mediate adhesion to NETs while other studies found unspecific binding to NETs underlying 
the process of NET-driven metastasis2,19,20. Consequently, degradation of NETs using DNase 
I has been found to limit metastases formation in animal models combining infection and 
tumor development2,19. Observations made in the here presented study suggest that histone 
H2a can also promote adhesion of tumor cells and promote metastases and perioperative 











Monocyte adhesion to endothelial cells is typically looked upon as a bi-cellular 
interaction37. However, such simplified model can be modified by accessory cells including 
platelets and neutrophils through direct interaction or release of secretory products with 
chemotactic effects38,39. In the context of atherogenesis NET release along the arterial 
endothelium appears an infrequent event14 making a major contribution of NETs as adhesive 
substrate for monocytes unlikely. Irrespective of this conclusion, depletion of NETs during 
early stages of atherosclerosis has repeatedly been shown to limit lesion size and macrophage 
accumulation40,41. Whether reduced macrophage accumulation in these studies is a 
consequence of lowered monocyte adhesion and possibly processes described in this study 
remains to be determined. In an acute inflammatory setting, such as a LPS challenge, 
however, luminal NET burden increases and herewith the chance for monocytes to adhere to 
NETs in this location. Based on our in vitro experiments it seems unlikely that histone H2a is 
deposited on the arterial endothelium as digestion of NETs on endothelial cells prevents 
monocyte adhesion. Yet another intriguing aspect of NETs in luminal location is their 
potential contribution to endothelial erosion. Previous reports have pointed to a mechanism by 
which NETs released at sites of disturbed flow contribute to endothelial cell death and 
subsequent endothelial denudation42,43. Further studies are required to investigate if NET-
resident cytotoxic components such as histones26,44 contribute to this process.  
While our study aims at understanding the acute effect of LPS on atherosclerosis 
development, others have reported the impact of chronic LPS delivery45. In such setting 
atherosclerotic plaques of mice receiving LPS are infiltrated by NK1.1 cells and T cells 
together promoting a proinflammatory microenvironment. In addition, activated lymphocytes 
populated the adventitia in these mice. In a similar disease model, the Apolipoprotein C-I-
dependent activation of macrophages was found to be crucial46. Thus far, however, the 










atherosclerosis has not been studied. One limiting factor may be the development of 
neutrophilic myeloid derived suppressor cells in the spleens of mice chronically challenged 
with LPS47 and future studies need to clarify the importance of neutrophils in such settings.  
Infections in cardiovascular risk patients increase the chance of cardiovascular 
complications several-fold within the first three weeks after an infection several fold. We here 
identify a mechanism centered on extracellular histone H2a which induces adhesion and 
recruitment of monocytes. While data from the CANTOS trial reveal the overall positive 
effects of anti-inflammation therapy in the context of atherosclerosis, neutralization of IL1β 
was also associated to heightened risk of bacterial infections48. Therapeutic neutralization of 
histone H2a will likely not be linked to such adverse side effects as the antimicrobial actions 
of histone H2a can be compensated by the abundance of other antimicrobial polypeptides 
residing within NETs. In addition, the strict focus on infection-associated cardiovascular 
complications will be relevant to a very short time window of now more than three weeks 
after infection and can be combined with standard antibiotic treatment. Thus, targeting histone 
H2a may stand out as an innovative way to lower arterial monocyte recruitment accelerated 
by infection while coming with limited intrinsic side effects.     
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Figure 1. Endotoxinemia accelerates atherosclerosis. (A) Experimental setup. Apoe-/- or 
Apoe-/-Cx3cr1GFP mice were fed a HFD for 4 weeks and treated with either PBS (ctrl) or with 
LPS (1mg/kg BW). Another LPS-treated group received a BB Cl-amidine (BB Cl-A, 1mg/kg 
BW) 12 h before and along with LPS injection. (B) Aortic root lesion size analyzed in HE-
stained sections. Representative images, scale bar 50 µm. (C/D) Lesional neutrophils (Ly6G+ 
cells) (C) and macrophages (Mac2+ cells) (D) quantified in root sections. Representative 
immunofluorescence images showing lesional neutrophil (red), Mac2+ positive cells (grey) 
and nuclei (DAPI, blue), scale bar 50 µm. (E/F) Quantification of luminally adherent 
neutrophils (E) and monocytes (F). (G) Representative intravital microscopy (IVM) images of 
the carotid artery of Apoe-/-Cx3cr1GFP mice. DNA is stained with DAPI, scale bar 50 µm. 
NET-like structures as identified by automized image analyzes are marked up with Asterisks. 
(H) Count of luminal NET-like structures in left common carotid artery. Data are analyzed by 
one-way ANOVA with Tukey's multiple comparisons test (B, D, E, F, H) or Kruskal-Wallis 
test with Dunn’s multiple comparisons test (C); *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001. All data are presented as mean±SEM. 
 
Figure 2. Monocyte adhesion to NETs is receptor independent. In vitro monocyte 
adhesion to expelled NETs under static or flow conditions. (A/B) Monocytes were added to 
neutrophils (ctrl) or NETting neutrophils (induced by A23187) and adhesion was quantified 
by a fluorescence plate reader. NETs were also degraded by DNase I. Representative 
microscopic image (B) of monocytes (violet) adherent to NETs (green; neutrophils red), scale 
bar 50 µm. (C/D) Monocytes were perfused at 0.5 dyne/cm2 over neutrophils, NETs, or 
degraded NETs and their adhesion was quantified manually. Representative microscopic 










(E-G) Monocytes where pre-treated with antagonists or antibodies to chemokine receptors 
(E), Toll-like receptors (F), or integrins (G) prior to incubation with NETs. (H/I) Monocytes 
fixed with PFA or treated with pertussis toxin (PTx) were used in static (H) or flow (I) 
adhesion assays. Data are analyzed by one-way ANOVA with Tukey's multiple comparisons 
test (A, H, G) or Kruskal-Wallis test with Dunn's multiple comparisons test (C, E, F, I); 
*p≤0.05, **p≤0.01, ***p≤0.001, **** p≤0.0001. All data are presented as mean±SEM. 
 
Figure 3. Monocyte adhesion to NETs in regulated by cationic histone H2a. (A/B) ζ-
potential analysis of isolated monocytes treated with Ch-sulfate (A) or oleylamine (B). (C) 
Pearson correlation of monocyte adhesion to NETs versus monocyte ζ-potential. (D) Scheme 
of single cell atomic force microscopy (AFM) force spectroscopy. Monocytes were probed on 
expelled NETs at 200 pN contact force. (E-G) Representative force curves of native 
monocytes (E) or monocytes treated with Ch-sulfate (F) or oleylamine (G) probed on NETs. 
(H/I) Quantification of the area under the curve reflecting the energy required to rupture the 
monocyte-NET interaction. (J) Proteome analysis of NET resident proteins. Circle size 
reflects protein abundance, while color codes for charge (red cationic, green anionic). (K) 
Monocyte adhesion to NETs pre-incubated with antibodies to indicated NET-associated 
proteins. (L) Representative immunofluorescence confocal microscopy image showing the 
tight interaction between NET resident histone H2a and a NET-bound monocyte, scale bar 3 
µm. Displayed is a xy projection (DNA gray, monocyte green, histone H2a red) and a zoom-
in underneath (monocyte green, histone H2a red). The right two panels represent a top view 
(xz) of the zoom-in area thus visualizing the interface between the monocyte (green) and 
NET-resident histone H2a (red). In the right panel the monocyte is outlined (dashed line). (M) 
Representative confocal microscopy images of histone H2a binding monocyte in a charge 










analyzed by unpaired t-test (A, B, H, I) or Kruskal-Wallis test with Dunn's multiple 
comparisons test (K); *p≤0.05, **p≤0.01, ***p≤0.001. All data are presented as mean±SEM. 
HNP, human neutrophil peptides; MPO, myeloperoxidase; PR3, proteinase 3; NE, neutrophil 
elastase; CatG, cathepsin G.  
Figure 4. Neutralization of histone H2a inhibits endotoxin-induced arterial myeloid cell 
recruitment and atheroprogression. (A) Experimental outline. Apoe-/-Cx3cr1GFP were fed a 
HFD for 4 weeks, treated with LPS (1 mg/kg, 4h) and injected with isotype respective control 
(IgG), or a histone H2a-targeting antibody (anti-H2a). (B-D) Intravital microscopy was used 
to quantify luminal NET-like structures (B) in the left carotid artery as well as adherent 
neutrophils (C) and monocytes (D). (E) The structure of histone H2a (magenta), CHIP 
(orange) and the histone H2a-CHIP complex which was derived from protein-protein docking 
and molecular dynamic simulation. CHIP bound and interacted with the N-terminal part of 
histone H2a. The electrostatic interactions between Arg or Lys of Histone H2a (green sticks) 
with Glu or Asp of CHIP (cyan sticks) as well as hydrogen bonds (displayed as dash lines) 
help to stabilize the complex formation between histone H2a and CHIP. (F-I) 
Pharmacological interruption of histone H2a monocyte-binding was validated in static 
adhesion assays (F) as well as by single cell force spectroscopy (G-I). (J-Q) In vivo validation 
of therapeutic effect of CHIP in endotoxin-accelerated atherosclerosis. (J) Experimental 
outline. Apoe-/-Cx3cr1GFP were fed a HFD for 4 weeks, treated with LPS (1 mg/kg, 4h) and 
injected with vehicle or CHIP (5 mg/kg). (K-M) Intravital microscopy was used to quantify 
luminal NET-like structures (K) in the left carotid artery as well as adherent neutrophils (L) 
and monocytes (M). (N) Aortic root lesion size analyzed after HE staining. Quantification of 
Lesional neutrophils (Ly6G+ cells) (O), and macrophages (Mac2+ cells) (P). (Q) 









(DAPI, blue), scale bar 50 µm. Data are analyzed by Mann-Whitney test (B, C, D, F, G, O) or 
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